Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AML

Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AML

Abstract Olutasidenib is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) that was recently approved by the US FDA for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring mutant IDH1. In the pivotal Phase II trial of olutas...

Full description

Saved in:
Bibliographic Details
Main Authors: Justin Watts, Tiffany Nong, Katarina Micin, Deborah Soong, Ellen Madarang, Maurizio Affer, Shefali Mehra, Jessica Alvarez Lesmes, Jennifer Chapman, Yi Zhou, Amber Thomassen, Terrence Bradley, Tulasigeri Totiger, Ronan Swords, Justin Taylor
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-025-01013-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41698-025-01013-5

Similar Items